Navigation Links
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Date:6/3/2013

THOUSAND OAKS, Calif., June 3, 2013 /PRNewswire/ -- ImmunGene, Inc. today announced that pre‑clinical studies of its novel anti‑CD20 antibody-interferon alpha fusion protein, IGN002, demonstrated superior anti‑lymphoma activity against numerous cell lines in vitro and against established human xenograft tumors grown in mice. The findings were presented in the Developmental Therapeutics - Immunotherapy poster session on Saturday, June 1, at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago (abstract #3024).

"The unique combination of IGN002's potent anti-proliferative and direct apoptosis effects in addition to antibody‑dependent cellular cytotoxicity and enhanced complement-dependent cytotoxicity has not been seen with any other CD20‑targeted agent," stated John Timmerman , MD, Associate Professor of Medicine, University of California, Los Angeles (UCLA) Division of Hematology‑Oncology and senior author of the study.

The presentation highlights the rapid progress being made in the development of a new class of anti-cancer biotherapeutics which use antibody-interferon alpha fusion technology. This technology was developed by Sherie Morrison , PhD, Distinguished Professor of Microbiology, Immunology, and Molecular Genetics at UCLA. Part of the pre-clinical research for IGN002 has been done in collaboration with the laboratories of Timmerman and Morrison, who are members of UCLA's Jonsson Comprehensive Cancer Center, and funded by The Leukemia & Lymphoma Society, the UCLA/CalTech Joint Center for Translational Medicine, and the NIH/National Cancer Institute.

"Antibody‑fusion proteins are designed to be inactive at therapeutic doses in the bloodstream while highly potent in targeting and killing cancer cells. We believe this approach is likely to spare healthy cells and may reduce many of the known toxic effects of systemically administered cytokines while greatly enhancing the anti-tumor activity of antibodies," said Iqbal Grewal , PhD, DSc, Chief Scientific Officer at ImmunGene. "We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014."

About IGN002

IGN002, a fusion molecule of anti-CD20 antibody and interferon alpha, two clinically validated anti‑cancer drugs, is designed to to deliver therapeutically effective doses of interferon alpha to CD20-expressing lymphoma cells to exert direct suppression of tumor cell growth and engage multiple anti-tumor immunologic effector mechanisms, leading to substantially improved efficacy while avoiding the systemic toxicity seen with free interferon.

As announced in May 2013, Valor Biotherapeutics, a joint venture between ImmunGene and Caliber Biotherapeutics, has partnered with The Leukemia & Lymphoma Society (LLS) to co-fund the completion of pre-clinical development, manufacturing, and a phase I clinical trial for IGN002.

About ImmunGene, Inc.

ImmunGene is a privately held biotechnology company focused on the development of proprietary antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and other diseases. ImmunGene has several programs at various stages of development. ImmunGene is funded by federal government grants including the NIH-SBIR and by private investors including several biotechnology executives. More information can be found at: www.immungene.com.

About Valor Biotherapeutics, LLC

Valor Biotherapeutics, a joint venture between ImmunGene and Caliber Biotherapeutics (www.caliberbio.com), is focused on the clinical development and commercialization of the next generation of monoclonal antibody-based therapeutics to treat cancer. For more information, please visit: www.valorbio.com.


'/>"/>
SOURCE ImmunGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
2. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
3. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
6. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... February 11, 2016 Jeffrey Zucker ... Clinical Trials, will present at this year,s Summit for Clinical ... Regency in Miami, FL. Zucker will ... optimize study execution, supporting SCOPE,s "Improving Site Study Activation and ... on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... 2016  Community pharmacists can help improve medication adherence ... through a custom-built medication synchronization program, Cardinal Health MedSync ... at Schieber Family Pharmacy in ... of patients enrolled in this medication synchronization program, which ... for the patient, and it,s a win for us ...
(Date:2/11/2016)... , Feb. 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by ... brother, Michael, has completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Yisrayl Hawkins, Pastor ... article this week that uncovers what he says are the real facts surrounding all ... the Bible from parents and Sunday school teachers, and Yisrayl says there is more ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... ... 11, 2016 , ... SPH Analytics announced today that ... health solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership ... the contract were not disclosed. , As the healthcare market moves towards quality-based ...
(Date:2/11/2016)... Tampa, FL (PRWEB) , ... February 11, 2016 , ... ... Tampa Bay Lightning take on the St. Louis Blues at the Amalie Arena. The ... only portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ranked among the top five firms in the “2015/2016 Best in KLAS: Software ... and Staffing. KLAS is a research and insights firm on a global mission ...
Breaking Medicine News(10 mins):